Voyager Therapeutics Advances Alzheimer’s Drug After Promising Trial Results

Voyager Therapeutics has taken a major step forward in Alzheimer’s research with encouraging results from its early-stage trial of VY7523, an experimental anti-tau antibody. The study, which tested single doses of the drug in 48 healthy volunteers, found that VY7523 was well tolerated across all dose levels, with no serious side effects or infusion reactions. These findings reinforce the drug’s potential to slow the spread of tau, a protein linked to Alzheimer’s progression. With these promising results, Voyager has now launched a multiple-dose trial in patients with early Alzheimer’s, aiming to gather more insights into its long-term effects.

Dr. Toby Ferguson, Voyager’s Chief Medical Officer, expressed optimism about the drug’s best-in-class potential, highlighting its specificity in targeting pathological tau and its strong preclinical data showing a 70% reduction in tau spread. The next phase of the trial will include advanced PET imaging to track tau progression in 52 Alzheimer’s patients, with key data expected in late 2026. As Alzheimer’s treatments continue to evolve, Voyager’s work adds to the growing excitement around new approaches to slowing disease progression and improving patient outcomes.